Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiation Tolerance | 22 | 2021 | 484 | 4.490 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 31 | 2021 | 5171 | 2.650 |
Why?
|
Radiation-Sensitizing Agents | 9 | 2021 | 358 | 2.430 |
Why?
|
Lung Neoplasms | 47 | 2022 | 13019 | 2.360 |
Why?
|
Relative Biological Effectiveness | 7 | 2019 | 323 | 2.050 |
Why?
|
Radiosurgery | 13 | 2022 | 1309 | 1.930 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 8 | 2015 | 147 | 1.870 |
Why?
|
DNA Repair | 19 | 2021 | 2042 | 1.680 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 7 | 2021 | 1683 | 1.410 |
Why?
|
Radiobiology | 5 | 2020 | 85 | 1.270 |
Why?
|
Radiation Injuries | 9 | 2020 | 1178 | 1.230 |
Why?
|
DNA Damage | 13 | 2021 | 2423 | 1.210 |
Why?
|
DNA Breaks, Double-Stranded | 11 | 2019 | 589 | 1.190 |
Why?
|
Rad51 Recombinase | 12 | 2016 | 188 | 1.130 |
Why?
|
Recombination, Genetic | 12 | 2013 | 1586 | 1.070 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 8 | 2020 | 1622 | 1.030 |
Why?
|
Tumor Suppressor Protein p53 | 10 | 2019 | 2948 | 1.000 |
Why?
|
Neoplasms | 23 | 2023 | 21596 | 0.970 |
Why?
|
Fanconi Anemia | 4 | 2016 | 319 | 0.860 |
Why?
|
Thoracic Wall | 3 | 2020 | 201 | 0.850 |
Why?
|
Radiotherapy | 10 | 2013 | 1525 | 0.810 |
Why?
|
Molecular Targeted Therapy | 7 | 2021 | 2723 | 0.800 |
Why?
|
Radiotherapy Dosage | 13 | 2021 | 2876 | 0.760 |
Why?
|
Phthalazines | 3 | 2018 | 361 | 0.730 |
Why?
|
Antineoplastic Agents | 16 | 2021 | 13655 | 0.720 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2016 | 806 | 0.710 |
Why?
|
BRCA1 Protein | 6 | 2015 | 1145 | 0.690 |
Why?
|
Head and Neck Neoplasms | 8 | 2024 | 2712 | 0.640 |
Why?
|
Esophagus | 4 | 2021 | 1017 | 0.620 |
Why?
|
Uncertainty | 2 | 2013 | 725 | 0.600 |
Why?
|
DNA Replication | 4 | 2021 | 1397 | 0.600 |
Why?
|
Fibroblasts | 6 | 2010 | 4143 | 0.600 |
Why?
|
Protein Kinase Inhibitors | 7 | 2020 | 5522 | 0.590 |
Why?
|
Cell Line, Tumor | 22 | 2024 | 16665 | 0.570 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2019 | 731 | 0.550 |
Why?
|
Recombinases | 1 | 2016 | 67 | 0.540 |
Why?
|
Gastroenterology | 1 | 2021 | 534 | 0.520 |
Why?
|
Osteopontin | 1 | 2017 | 296 | 0.520 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2020 | 5163 | 0.500 |
Why?
|
Protons | 2 | 2021 | 1126 | 0.500 |
Why?
|
Fanconi Anemia Complementation Group A Protein | 2 | 2011 | 46 | 0.490 |
Why?
|
Esophagitis | 1 | 2015 | 152 | 0.470 |
Why?
|
Reactive Oxygen Species | 2 | 2019 | 2077 | 0.470 |
Why?
|
Cell Survival | 9 | 2021 | 5872 | 0.450 |
Why?
|
Small Molecule Libraries | 1 | 2019 | 721 | 0.440 |
Why?
|
Endonucleases | 1 | 2016 | 381 | 0.440 |
Why?
|
Cisplatin | 5 | 2023 | 1637 | 0.440 |
Why?
|
Radiation Pneumonitis | 3 | 2016 | 104 | 0.440 |
Why?
|
Thoracic Neoplasms | 1 | 2015 | 268 | 0.430 |
Why?
|
Piperazines | 3 | 2018 | 2488 | 0.420 |
Why?
|
ras Proteins | 2 | 2014 | 1060 | 0.410 |
Why?
|
Mutation | 23 | 2021 | 29717 | 0.380 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2015 | 1769 | 0.370 |
Why?
|
DNA | 5 | 2021 | 7289 | 0.360 |
Why?
|
Apoptosis | 6 | 2019 | 9715 | 0.360 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2023 | 2229 | 0.350 |
Why?
|
Humans | 103 | 2024 | 742088 | 0.350 |
Why?
|
Etoposide | 1 | 2011 | 637 | 0.350 |
Why?
|
Fanconi Anemia Complementation Group Proteins | 1 | 2010 | 100 | 0.350 |
Why?
|
Quinazolines | 3 | 2014 | 1355 | 0.340 |
Why?
|
Combined Modality Therapy | 13 | 2021 | 8621 | 0.330 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2015 | 4029 | 0.330 |
Why?
|
Photons | 4 | 2019 | 587 | 0.320 |
Why?
|
Organoplatinum Compounds | 1 | 2010 | 408 | 0.320 |
Why?
|
Pneumonectomy | 1 | 2015 | 1093 | 0.320 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2015 | 3471 | 0.300 |
Why?
|
Cell Cycle Proteins | 5 | 2011 | 3444 | 0.280 |
Why?
|
Guidelines as Topic | 1 | 2013 | 1402 | 0.280 |
Why?
|
DNA-Binding Proteins | 10 | 2016 | 9639 | 0.280 |
Why?
|
G1 Phase | 2 | 2015 | 415 | 0.280 |
Why?
|
Chromosome Breakage | 1 | 2006 | 173 | 0.270 |
Why?
|
Signal Transduction | 7 | 2018 | 23387 | 0.270 |
Why?
|
Cobalt Radioisotopes | 2 | 2016 | 76 | 0.270 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2016 | 384 | 0.260 |
Why?
|
Neoplasm Staging | 7 | 2019 | 11001 | 0.260 |
Why?
|
Organs at Risk | 4 | 2019 | 346 | 0.250 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4553 | 0.250 |
Why?
|
Medical Oncology | 3 | 2023 | 2235 | 0.250 |
Why?
|
Cell Proliferation | 6 | 2021 | 10472 | 0.240 |
Why?
|
Chromones | 1 | 2024 | 154 | 0.240 |
Why?
|
Endodeoxyribonucleases | 2 | 2016 | 162 | 0.230 |
Why?
|
Mice, Nude | 3 | 2019 | 3689 | 0.230 |
Why?
|
Pharmaceutical Preparations | 2 | 2021 | 1071 | 0.220 |
Why?
|
Radiation Dosage | 5 | 2017 | 1927 | 0.220 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3800 | 0.210 |
Why?
|
Chromatin | 1 | 2014 | 2917 | 0.210 |
Why?
|
Animals | 29 | 2021 | 168561 | 0.210 |
Why?
|
Radiation, Ionizing | 4 | 2011 | 258 | 0.200 |
Why?
|
Mice | 18 | 2021 | 81045 | 0.200 |
Why?
|
Radiation Oncology | 2 | 2018 | 554 | 0.200 |
Why?
|
Mitomycin | 2 | 2013 | 259 | 0.200 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3611 | 0.200 |
Why?
|
Parental Leave | 1 | 2021 | 78 | 0.190 |
Why?
|
Cell Line | 9 | 2015 | 15994 | 0.190 |
Why?
|
Transplantation, Heterologous | 2 | 2019 | 2382 | 0.190 |
Why?
|
Neoplastic Stem Cells | 3 | 2017 | 1376 | 0.180 |
Why?
|
Melanoma, Experimental | 1 | 2003 | 559 | 0.180 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9274 | 0.180 |
Why?
|
Breast | 1 | 2009 | 1958 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2020 | 9185 | 0.180 |
Why?
|
Cranial Irradiation | 2 | 2020 | 401 | 0.180 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2022 | 153 | 0.170 |
Why?
|
Aged, 80 and over | 18 | 2021 | 57683 | 0.170 |
Why?
|
Alginates | 1 | 2021 | 250 | 0.170 |
Why?
|
Clinical Trials as Topic | 7 | 2021 | 7901 | 0.170 |
Why?
|
Aniline Compounds | 1 | 2024 | 983 | 0.170 |
Why?
|
Female | 42 | 2023 | 379592 | 0.170 |
Why?
|
S Phase | 1 | 2000 | 423 | 0.160 |
Why?
|
Histones | 2 | 2011 | 2597 | 0.160 |
Why?
|
Bicarbonates | 1 | 2019 | 313 | 0.160 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2019 | 236 | 0.160 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2020 | 252 | 0.160 |
Why?
|
Genes, p53 | 1 | 2000 | 755 | 0.150 |
Why?
|
Policy | 1 | 2021 | 504 | 0.150 |
Why?
|
Oxygen | 1 | 2009 | 4169 | 0.150 |
Why?
|
Lung | 6 | 2019 | 9826 | 0.150 |
Why?
|
Physicians, Women | 1 | 2023 | 487 | 0.140 |
Why?
|
Oxidative Stress | 1 | 2008 | 3081 | 0.140 |
Why?
|
Gene Conversion | 3 | 2008 | 71 | 0.140 |
Why?
|
Thiazoles | 1 | 2024 | 1484 | 0.140 |
Why?
|
Tumor Burden | 4 | 2017 | 1905 | 0.140 |
Why?
|
Carcinoma, Medullary | 1 | 1997 | 123 | 0.140 |
Why?
|
Cesium Radioisotopes | 1 | 2016 | 36 | 0.140 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2019 | 265 | 0.140 |
Why?
|
Aged | 24 | 2022 | 162944 | 0.130 |
Why?
|
Research Report | 1 | 2019 | 355 | 0.130 |
Why?
|
Phenylurea Compounds | 1 | 2019 | 526 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 8 | 2020 | 6534 | 0.130 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2019 | 651 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 11472 | 0.130 |
Why?
|
Male | 31 | 2023 | 349538 | 0.130 |
Why?
|
Brain Neoplasms | 4 | 2020 | 8829 | 0.130 |
Why?
|
Middle Aged | 25 | 2021 | 213127 | 0.120 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2018 | 448 | 0.120 |
Why?
|
History, 20th Century | 5 | 2006 | 2739 | 0.120 |
Why?
|
Neoplasm Metastasis | 4 | 2020 | 4839 | 0.120 |
Why?
|
Cell Cycle | 3 | 2018 | 2964 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2004 | 2940 | 0.120 |
Why?
|
Linear Energy Transfer | 1 | 2015 | 154 | 0.120 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2024 | 2938 | 0.120 |
Why?
|
Rhabdomyosarcoma | 1 | 1997 | 382 | 0.120 |
Why?
|
Protein Kinase C-alpha | 1 | 2014 | 112 | 0.120 |
Why?
|
Cell Division | 2 | 2000 | 4564 | 0.110 |
Why?
|
Tumor Stem Cell Assay | 1 | 2013 | 118 | 0.110 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2019 | 3557 | 0.110 |
Why?
|
Flow Cytometry | 2 | 2016 | 5975 | 0.110 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 1066 | 0.110 |
Why?
|
Meta-Analysis as Topic | 1 | 1998 | 1342 | 0.110 |
Why?
|
Biopsy | 2 | 2019 | 6756 | 0.110 |
Why?
|
Pyrazines | 1 | 2019 | 1231 | 0.110 |
Why?
|
Plasmids | 4 | 2004 | 2305 | 0.110 |
Why?
|
Thymus Neoplasms | 1 | 2015 | 268 | 0.110 |
Why?
|
Carcinoma, Lobular | 1 | 1997 | 484 | 0.110 |
Why?
|
Congresses as Topic | 1 | 2017 | 764 | 0.110 |
Why?
|
RNA Interference | 2 | 2011 | 2890 | 0.110 |
Why?
|
Exodeoxyribonucleases | 1 | 2013 | 176 | 0.110 |
Why?
|
Radiography | 2 | 2015 | 7010 | 0.100 |
Why?
|
NIH 3T3 Cells | 1 | 2013 | 677 | 0.100 |
Why?
|
Treatment Outcome | 14 | 2023 | 62966 | 0.100 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2013 | 441 | 0.100 |
Why?
|
Thymidine | 1 | 2011 | 309 | 0.100 |
Why?
|
Cells, Cultured | 5 | 2011 | 19223 | 0.100 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 4455 | 0.100 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2011 | 87 | 0.100 |
Why?
|
Lymphocytes | 1 | 2019 | 2614 | 0.090 |
Why?
|
Fluorescent Antibody Technique | 2 | 2015 | 2505 | 0.090 |
Why?
|
Models, Theoretical | 2 | 2020 | 3584 | 0.090 |
Why?
|
Antigens, Nuclear | 2 | 2008 | 192 | 0.090 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2011 | 121 | 0.090 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2016 | 1372 | 0.090 |
Why?
|
Models, Biological | 5 | 2021 | 9581 | 0.090 |
Why?
|
Cell Hypoxia | 1 | 2013 | 675 | 0.090 |
Why?
|
Fanconi Anemia Complementation Group C Protein | 1 | 2010 | 21 | 0.090 |
Why?
|
Germany | 3 | 1998 | 860 | 0.090 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 284 | 0.090 |
Why?
|
Oncogenes | 1 | 2016 | 1263 | 0.090 |
Why?
|
Rectal Neoplasms | 1 | 2019 | 1195 | 0.090 |
Why?
|
Reproducibility of Results | 3 | 2021 | 19862 | 0.090 |
Why?
|
History, 19th Century | 2 | 2006 | 720 | 0.090 |
Why?
|
Exonucleases | 1 | 2009 | 47 | 0.090 |
Why?
|
Genes, erbB-1 | 1 | 2010 | 161 | 0.090 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1799 | 0.090 |
Why?
|
Breast Neoplasms | 5 | 2009 | 20774 | 0.090 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1997 | 1101 | 0.090 |
Why?
|
Education, Medical, Graduate | 1 | 2021 | 2283 | 0.090 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2013 | 692 | 0.080 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7276 | 0.080 |
Why?
|
Frozen Sections | 1 | 2009 | 155 | 0.080 |
Why?
|
Immunologic Factors | 1 | 2018 | 1575 | 0.080 |
Why?
|
Benzimidazoles | 1 | 2014 | 848 | 0.080 |
Why?
|
Transcriptional Activation | 3 | 2011 | 1782 | 0.080 |
Why?
|
Cell Line, Transformed | 1 | 2010 | 898 | 0.080 |
Why?
|
Cross-Linking Reagents | 1 | 2011 | 694 | 0.080 |
Why?
|
Retrospective Studies | 10 | 2022 | 77098 | 0.080 |
Why?
|
3T3 Cells | 2 | 2000 | 1101 | 0.080 |
Why?
|
Reference Values | 1 | 2015 | 4982 | 0.080 |
Why?
|
Hippocampus | 1 | 2020 | 3661 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 2906 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1659 | 0.070 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2011 | 713 | 0.070 |
Why?
|
Transfection | 2 | 2013 | 5892 | 0.070 |
Why?
|
Tumor Cells, Cultured | 2 | 2013 | 6313 | 0.070 |
Why?
|
Neutrophils | 1 | 2019 | 3711 | 0.070 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 2 | 2008 | 170 | 0.070 |
Why?
|
Respiration | 1 | 2013 | 1645 | 0.070 |
Why?
|
Genomics | 2 | 2023 | 5692 | 0.070 |
Why?
|
Soft Tissue Neoplasms | 1 | 1995 | 1361 | 0.070 |
Why?
|
Prospective Studies | 5 | 2022 | 53187 | 0.070 |
Why?
|
France | 2 | 1998 | 517 | 0.070 |
Why?
|
Movement | 1 | 2013 | 1470 | 0.070 |
Why?
|
Microscopy, Fluorescence | 1 | 2013 | 2699 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10943 | 0.070 |
Why?
|
Linear Models | 1 | 2016 | 5948 | 0.070 |
Why?
|
Sarcoma | 1 | 1997 | 1895 | 0.070 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2006 | 1086 | 0.060 |
Why?
|
Crossing Over, Genetic | 2 | 2001 | 95 | 0.060 |
Why?
|
Mitochondria | 1 | 2018 | 3520 | 0.060 |
Why?
|
Genotype | 3 | 2017 | 12946 | 0.060 |
Why?
|
Manure | 1 | 2004 | 12 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5133 | 0.060 |
Why?
|
Drug Resistance | 1 | 2010 | 1608 | 0.060 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2023 | 104 | 0.060 |
Why?
|
Base Sequence | 4 | 2015 | 12797 | 0.060 |
Why?
|
Sphingomyelin Phosphodiesterase | 1 | 2003 | 91 | 0.060 |
Why?
|
Ubiquitin | 1 | 2008 | 849 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2011 | 9941 | 0.060 |
Why?
|
Spinal Cord | 1 | 2011 | 1807 | 0.060 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2006 | 1723 | 0.060 |
Why?
|
Ammonia | 1 | 2004 | 239 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2014 | 3465 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2013 | 2266 | 0.050 |
Why?
|
Bioreactors | 1 | 2004 | 236 | 0.050 |
Why?
|
Tumor Microenvironment | 3 | 2019 | 3564 | 0.050 |
Why?
|
Immunotherapy | 1 | 2018 | 4414 | 0.050 |
Why?
|
Biomedical Research | 1 | 2018 | 3306 | 0.050 |
Why?
|
Catheter Ablation | 2 | 2014 | 2746 | 0.050 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2008 | 1333 | 0.050 |
Why?
|
Homeodomain Proteins | 1 | 2011 | 2417 | 0.050 |
Why?
|
DNA Mutational Analysis | 2 | 2010 | 4187 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2017 | 4249 | 0.050 |
Why?
|
Monte Carlo Method | 2 | 2019 | 1254 | 0.050 |
Why?
|
Calcium Chloride | 1 | 2021 | 77 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2017 | 39004 | 0.050 |
Why?
|
Survival Analysis | 3 | 2020 | 10248 | 0.050 |
Why?
|
Treatment Failure | 2 | 2017 | 2615 | 0.050 |
Why?
|
Postoperative Care | 2 | 1997 | 1484 | 0.050 |
Why?
|
History, 21st Century | 1 | 2006 | 1533 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2024 | 890 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2002 | 617 | 0.040 |
Why?
|
Inflammation | 1 | 2019 | 10578 | 0.040 |
Why?
|
Rats | 3 | 2000 | 24265 | 0.040 |
Why?
|
Cystectomy | 1 | 2023 | 682 | 0.040 |
Why?
|
Cell Growth Processes | 1 | 2019 | 400 | 0.040 |
Why?
|
Trans-Activators | 1 | 2008 | 2924 | 0.040 |
Why?
|
Ohio | 1 | 2019 | 337 | 0.040 |
Why?
|
Time Factors | 5 | 2020 | 40054 | 0.040 |
Why?
|
Neoplasms, Experimental | 1 | 2003 | 1274 | 0.040 |
Why?
|
Societies, Medical | 2 | 2023 | 3740 | 0.040 |
Why?
|
Mice, SCID | 1 | 2003 | 2715 | 0.040 |
Why?
|
Genomic Instability | 2 | 2015 | 695 | 0.040 |
Why?
|
Codon | 1 | 2000 | 611 | 0.040 |
Why?
|
Cultural Diversity | 1 | 2021 | 358 | 0.040 |
Why?
|
Triazines | 1 | 2020 | 316 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2019 | 876 | 0.040 |
Why?
|
Alanine | 1 | 2000 | 572 | 0.040 |
Why?
|
Laboratories | 1 | 2021 | 461 | 0.040 |
Why?
|
Standard of Care | 1 | 2021 | 562 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6347 | 0.040 |
Why?
|
Analysis of Variance | 2 | 2016 | 6365 | 0.040 |
Why?
|
Gene Amplification | 1 | 2001 | 1062 | 0.040 |
Why?
|
Prognosis | 4 | 2019 | 29010 | 0.040 |
Why?
|
Disease Progression | 3 | 2020 | 13256 | 0.040 |
Why?
|
Early Detection of Cancer | 2 | 2022 | 3070 | 0.040 |
Why?
|
Saccharomyces cerevisiae Proteins | 2 | 2008 | 1884 | 0.040 |
Why?
|
Disease Models, Animal | 3 | 2018 | 18006 | 0.040 |
Why?
|
Survival Rate | 3 | 2019 | 12773 | 0.040 |
Why?
|
Up-Regulation | 2 | 2008 | 4211 | 0.030 |
Why?
|
Switzerland | 1 | 1996 | 254 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 281 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6891 | 0.030 |
Why?
|
Drug Combinations | 1 | 2021 | 1961 | 0.030 |
Why?
|
DNA Primers | 2 | 2015 | 2892 | 0.030 |
Why?
|
Nuclear Proteins | 2 | 2008 | 5851 | 0.030 |
Why?
|
Radiation Injuries, Experimental | 1 | 1996 | 91 | 0.030 |
Why?
|
Embryo, Mammalian | 1 | 2001 | 1692 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2023 | 3612 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 2006 | 18112 | 0.030 |
Why?
|
Comet Assay | 1 | 2015 | 71 | 0.030 |
Why?
|
Quality of Life | 1 | 2016 | 12730 | 0.030 |
Why?
|
Models, Genetic | 2 | 2002 | 3493 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2016 | 12344 | 0.030 |
Why?
|
Adult | 10 | 2017 | 213712 | 0.030 |
Why?
|
Benzamides | 1 | 2020 | 1378 | 0.030 |
Why?
|
United States | 3 | 2023 | 69693 | 0.030 |
Why?
|
Imidazoles | 1 | 2020 | 1205 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2022 | 20086 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 15494 | 0.030 |
Why?
|
Fluorouracil | 1 | 1997 | 1615 | 0.030 |
Why?
|
Cohort Studies | 3 | 2021 | 40450 | 0.030 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 24913 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 1983 | 0.020 |
Why?
|
Europe | 1 | 1998 | 3339 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2000 | 6382 | 0.020 |
Why?
|
Genes, Reporter | 2 | 2008 | 1547 | 0.020 |
Why?
|
Methotrexate | 1 | 1997 | 1720 | 0.020 |
Why?
|
HeLa Cells | 1 | 2016 | 3127 | 0.020 |
Why?
|
Rabbits | 1 | 1996 | 4886 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 1997 | 2906 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2018 | 8425 | 0.020 |
Why?
|
Menopause | 1 | 1997 | 1621 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 2935 | 0.020 |
Why?
|
Calcium | 1 | 2022 | 5753 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2001 | 3691 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2000 | 8300 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8333 | 0.020 |
Why?
|
Gene Expression | 1 | 2001 | 7790 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 600 | 0.020 |
Why?
|
Preoperative Care | 1 | 1997 | 2245 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 2 | 2011 | 2842 | 0.020 |
Why?
|
Research | 1 | 1996 | 1999 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2000 | 5095 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4751 | 0.020 |
Why?
|
BRCA2 Protein | 2 | 2002 | 790 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5180 | 0.020 |
Why?
|
Massachusetts | 1 | 2019 | 8662 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 1997 | 2714 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 602 | 0.020 |
Why?
|
Methylation | 1 | 2009 | 1107 | 0.020 |
Why?
|
DNA, Single-Stranded | 1 | 2008 | 353 | 0.020 |
Why?
|
Cricetulus | 1 | 2008 | 817 | 0.020 |
Why?
|
Binding Sites | 2 | 2006 | 6115 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2002 | 4823 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 783 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11363 | 0.020 |
Why?
|
CHO Cells | 1 | 2008 | 1407 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3701 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2009 | 1526 | 0.020 |
Why?
|
Replication Protein A | 1 | 2004 | 51 | 0.020 |
Why?
|
Research Design | 1 | 2020 | 5979 | 0.020 |
Why?
|
Cricetinae | 1 | 2008 | 2471 | 0.020 |
Why?
|
Fertilizers | 1 | 2004 | 24 | 0.020 |
Why?
|
Waste Disposal, Fluid | 1 | 2004 | 30 | 0.020 |
Why?
|
Incidence | 1 | 2022 | 20928 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2011 | 2006 | 0.010 |
Why?
|
Phosphorylation | 2 | 2006 | 8436 | 0.010 |
Why?
|
Radiology | 1 | 1997 | 2090 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9410 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2011 | 2968 | 0.010 |
Why?
|
Glioma | 1 | 1997 | 3388 | 0.010 |
Why?
|
Transcription Factors | 1 | 2001 | 12164 | 0.010 |
Why?
|
Kinetics | 1 | 2008 | 6474 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2006 | 1758 | 0.010 |
Why?
|
Gene Deletion | 1 | 2008 | 2751 | 0.010 |
Why?
|
Serine | 1 | 2004 | 828 | 0.010 |
Why?
|
Chloramphenicol O-Acetyltransferase | 1 | 1999 | 222 | 0.010 |
Why?
|
Comorbidity | 1 | 2014 | 10372 | 0.010 |
Why?
|
Risk | 1 | 2011 | 9679 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 13853 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2010 | 2002 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2008 | 3504 | 0.010 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2008 | 1860 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2004 | 2552 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12220 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2008 | 2915 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2011 | 12242 | 0.010 |
Why?
|
Young Adult | 2 | 2014 | 56350 | 0.010 |
Why?
|
Swine | 1 | 2004 | 5934 | 0.010 |
Why?
|
Protein Binding | 1 | 2004 | 9387 | 0.010 |
Why?
|
Air Pollutants | 1 | 2004 | 2814 | 0.010 |
Why?
|
Risk Factors | 1 | 2011 | 72145 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2002 | 12071 | 0.000 |
Why?
|